June 23, 2020
Dr. Talia Wegman Talks Genetic & Molecular Testing in Latinx Cancer Patients
MDNewsline recently interviewed international cancer researcher Dr. Talia Wegman to discuss the importance of molecular and genetic testing and cancer in Latinx patients. Dr Talia is a past National Cancer Institute (NCI) Division of Cancer Epidemiology & Genetics postdoctoral fellow and has been recognized in the U.S. and Mexico for her research in molecular genetics...
Radiotherapy for Prostate Cancer Adjusted During COVID-19
In a special article published online April 1 in Advances in Radiation Oncology, a framework is laid out for the management of radiotherapy for prostate cancer patients during the coronavirus disease 2019 (COVID-19) pandemic. Nicholas G. Zaorsky, M.D., from Penn State Cancer Institute in Hershey, and colleagues established recommendations and developed a Remote visit, and Avoidance,...
Local-Stage Prostate Cancer Incidence Rates Continue to Drop
Prostate cancer incidence rates decreased from 2005 to 2016 for local-stage disease among men aged ≥50 years but increased for regional- and distant-stage disease, according to a study published online May 20 in the Journal of the National Cancer Institute. Ahmedin Jemal, D.V.M., Ph.D., from the American Cancer Society in Atlanta, and colleagues examined trends...
Are Racial Disparities in Prostate Cancer Survival Tied to Region?
National, race-based differences in prostate cancer survival are due to regional variation, even for low-risk prostate cancer, according to a study published online March 31 in JAMA Network Open. Sean A. Fletcher, M.D., from Brigham and Women’s Hospital in Boston, and colleagues analyzed data from 17 geographic registries within the Surveillance, Epidemiology, and End Results database...
ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer
For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is associated with improved survival versus placebo in nonmetastatic, castration-resistant prostate cancer, according to two studies published online May 29 in the New England Journal of Medicine to coincide with the American Society...
Study Shows Lack Of Diversity Currently Plaguing Prostate Cancer Clinical Trials
Prostate cancer clinical trial participants are overwhelmingly white, according to a study published online June 5 in Cancer Epidemiology, Biomarkers & Prevention. Emily M. Rencsok, from the Harvard T.H. Chan School of Public Health in Boston, and colleagues analyzed 72 global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start...